<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05701358</url>
  </required_header>
  <id_info>
    <org_study_id>COMPLETE-2</org_study_id>
    <nct_id>NCT05701358</nct_id>
  </id_info>
  <brief_title>Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI &amp; Multivessel Disease</brief_title>
  <acronym>COMPLETE-2</acronym>
  <official_title>A Randomized Trial of Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization Strategies &amp; an Observational Study of Optical Coherence Tomography in Patients With Acute MI &amp; Multivessel Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy&#xD;
      of physiology-guided complete revascularization to angiography-guided complete&#xD;
      revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI)&#xD;
      or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery&#xD;
      disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention&#xD;
      (PCI).&#xD;
&#xD;
      COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of&#xD;
      patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COMPLETE-2 STUDY OBJECTIVES&#xD;
&#xD;
        1. To determine whether a strategy of physiology-guided complete revascularization is&#xD;
           non-inferior to a strategy of angiography-guided complete revascularization on the&#xD;
           efficacy composite outcome of cardiovascular (CV) death, new myocardial infarction (MI)&#xD;
           or ischemia-driven revascularization (IDR).&#xD;
&#xD;
        2. To determine whether a physiology-guided complete revascularization strategy is superior&#xD;
           to an angiography-guided complete revascularization strategy in reducing the safety&#xD;
           composite outcome of clinically significant bleeding, stroke, stent thrombosis or&#xD;
           contrast-associated acute kidney injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2023</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Time to first occurrence of the composite of CV death, new MI, or IDR</measure>
    <time_frame>at study completion, a minimum of 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Time to first occurrence of the composite of clinically significant bleeding, stroke, stent thrombosis, or contrast-associated acute kidney injury.</measure>
    <time_frame>at study completion, a minimum of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of the composite of CV death or new MI.</measure>
    <time_frame>at study completion, a minimum of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net clinical outcome: Time to first occurrence of the composite of CV death, new MI, clinically significant bleeding, stroke, stent thrombosis or contrast-associated acute kidney injury.</measure>
    <time_frame>at study completion, a minimum of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5100</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Physiology-guided Non-Culprit-Lesion (NCL) PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will have their physiology assessment using RFR and/or FFR of all qualifying NCLs that were identified prior to randomization. Other validated non-hyperemic physiology ratios (eg. iFR) may only be used when RFR is not available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided NCL PCI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to this group will undergo routine staged PCI of all qualifying NCLs that were identified prior to randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physiology-guided NCL PCI</intervention_name>
    <description>For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.</description>
    <arm_group_label>Physiology-guided Non-Culprit-Lesion (NCL) PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography-guided NCL PCI</intervention_name>
    <description>PCI will be performed as per local practice</description>
    <arm_group_label>Angiography-guided NCL PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients presenting with STEMI or type 1 NSTEMI and within 72 hours of successful&#xD;
             culprit-lesion PCI&#xD;
&#xD;
          2. Residual coronary artery disease defined as at least 1 additional non-infarct-related&#xD;
             coronary artery stenosis that meets all of the following criteria:&#xD;
&#xD;
               1. Amenable to successful treatment with PCI&#xD;
&#xD;
               2. At least 50% diameter stenosis by visual estimation&#xD;
&#xD;
               3. At least 2.5 mm in diameter&#xD;
&#xD;
          3. Planned complete revascularization strategy for qualifying MI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned or prior coronary artery bypass graft (CABG) surgery&#xD;
&#xD;
          2. Inability to clearly identify a culprit lesion for STEMI or NSTEMI based on&#xD;
             angiographic appearance and/or ECG changes and/or regional wall motion abnormalities&#xD;
&#xD;
          3. Prior PCI of a non-culprit lesion in a different vessel from the culprit lesion within&#xD;
             45 days of randomization&#xD;
&#xD;
          4. Planned medical treatment of all qualifying non-culprit lesions (i.e., no PCI)&#xD;
&#xD;
          5. Presence of severe non-culprit-lesion stenosis with reduced epicardial flow (TIMI flow&#xD;
             ≤ 2) or &gt;90% visual diameter stenosis&#xD;
&#xD;
          6. Presence of a chronic total occlusion (CTO) if it is the only qualifying non-culprit&#xD;
             lesion (patients with a CTO plus additional qualifying non-culprit lesions are&#xD;
             eligible)&#xD;
&#xD;
          7. The only qualifying non-culprit lesion is in the same vessel territory as the culprit&#xD;
             lesion&#xD;
&#xD;
          8. Baseline STEMI or NSTEMI was due to a suspected non-atherothrombotic mechanism such as&#xD;
             type 2 MI (supply-demand mismatch), including spontaneous coronary artery dissection&#xD;
             or coronary artery embolism&#xD;
&#xD;
          9. Non-cardiovascular co-morbidity with expected life expectancy &lt;2 years&#xD;
&#xD;
         10. Any other medical, geographic, or social factor making study participation impractical&#xD;
             or precluding 5 year follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamir Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shamir Mehta, MD</last_name>
    <phone>(905) 521-2100</phone>
    <email>smehta@mcmaster.ca</email>
  </overall_contact>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 25, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>April 27, 2023</last_update_submitted>
  <last_update_submitted_qc>April 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSTEMI</keyword>
  <keyword>STEMI</keyword>
  <keyword>multi-vessel disease</keyword>
  <keyword>optical coherence tomography</keyword>
  <keyword>FFR</keyword>
  <keyword>RFR</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

